EUCTR2012-000850-75-NL进行中（未招募）不适用
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
VU University Medical Center0 个研究点开始时间: 2012年5月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years
- •2. Receiving palliative care
- •3. Life expectancy = 2 weeks
- •4. Able to give informed consent
- •5. Receiving opioid treatment with either morphine sulphate, oxycodone or fentanyl
- •6. Opioid treatment, both
- •o On a regular schedule (not just as needed or rescue doses) for the control of pain or dyspnea for at least 2 weeks before the first dose of methylnaltrexone, and
- •o On a stable opioid regimen for at least 3 days before the first dose of methylnaltrexone. This is defined as no dose reduction of = 50%, dose increases are permitted. If rescue medication is prescribed of a different type of opioid than the regular dosed opioid, the rescue medication should be switched to the same type as the regular dosed opioid for at least 3 days before the first dose of methylnaltrexone.
- •7. Has diagnosis of constipation, defined as either
- •o < 3 bowel movements during the previous week by history and no clinically notable laxation* in the 24 hours before the first dose of methylnaltrexone, or
- •o No clinically notable laxation* in the 48 hours before the first dose of methylnaltrexone.
- •8. Constipation is defined as opioid induced, determined by investigator
- •9. On stable laxative regimen for = 3 days before the first dose of methylnaltrexone. This is defined as at least one type of laxative in an adequate dosing regimen, (e.g. macrogol 2 packets daily, magnesium(hydr)oxide 500 mg three times daily, bisacodyl 10 mg daily or sennoside A+B 10 ml daily) or at least two types of laxatives in a suboptimal dose with patient characteristics hampering optimal treatment.
- •10. If the subject is a woman with presumed child bearing potential; negative urine pregnancy test at screening
- •11. Surgically sterile or agrees to use a medically acceptable method of birth control or practice sexual abstinence for the duration of the methylnaltrexone treatment and the following 15 days. ~
- •* including laxation after rescue laxative or enema
- •~ not necessary for postmenopausal women
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 95
排除标准
- •1. Previous treatment with methylnaltrexone
- •2. Known or suspected mechanical gastrointestinal obstruction
- •3. Presence of an other cause of bowel dysfunction that is considered to be a major contribution to the constipation according to investigator
- •4. Presence of a peritoneal catheter for intraperitoneal chemotherapy or dialysis
- •5. Clinically relevant active diverticular disease
- •6. History of bowel surgery within 10 days before first dose of methylnaltrexone
- •7. Fecal ostomy
- •8. Use of vinca alkaloids within previous 4 months
- •9. Body weight <38 kg
- •10. Renal failure defined as EGFR <30 ml/min per 1.73m2 or requires dialysis.
- •11. Known or suspected allergy to methylnaltrexone or similar compounds (e.g. naltrexone or naloxone)
- •12. Participation in a study with investigational products within 30 days before first dose of methylnaltrexone.
- •13. Pregnant or nursing
- •14. Clinically important abnormalities that may interfere with participation or compliance to the study, determined by investigator
- •Additional exclusion criteria for the immunologic and angiogenic analysis part of the study:
- •15. Chemotherapy or treatment with tyrosine kinase inhibitor during 4 weeks before inclusion or treatment scheduled during participation in this study.
- •16. Treatment with high dose corticosteroids during 2 weeks before inclusion in this study. This is defined as the equivalent of 30 mg of prednisone per day for = 2 consecutive days.
研究者
相似试验
已完成
4 期
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone10017977constipationNL-OMON39494Vrije Universiteit Medisch Centrum195
招募中
不适用
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexoneconstipationmethylnaltrexoneopioidobstipatieNL-OMON27076VU University Medical Center195
招募中
3 期
Metformin and Body Mass Index of Patients under Treatment with SSRICondition 1: Obesity. Condition 2: Depression. Condition 3: Anxiety Disorders.Drug-induced obesityMajor depressive disorder, single episode, severe without psychotic featuresOther anxiety disordersE66.1F32.2IRCT20140102016035N3Rasht University of Medical Sciences60
招募中
3 期
Comparison of the effect of methylprednisolone and dexamethasone in prime solutioIRCT20170620034666N2Isfahan University of Medical Sciences62
已完成
3 期
The effect of magnesium in patients with attention deficit hyperactivity disorderIRCT20160813029327N19Islamic Azad University62